s. CoAprovel is indicated in patients whose blood pressure is not adequately controlled with a monotherapy, but also as initial therapy in patients at high risk or with markedly high baseline blood pressure or who are likely to need multiple drugs to achieve their blood pressure goals. A fixed-dose combination with amlodipine (Aprovasc) has been launched in various emerging markets. Aprovel and CoAprovel are marketed in approximately 80 countries. The main countries contributing to sales of Aprovel/Avapro/Karvea in 2015 were China and Japan. Renagel and Renvela Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate) are oral phosphate binders used by chronic kidney disease (CKD) patients on dialysis, as well as late stage CKD patients in Europe to treat a condition called hyperphosphatemia, or elevated phosphorus levels, which is associated with heart and bone disease. Renvela is a second generation, buffered phosphate binder. In the E.U., Renvela is also approved to treat CKD patients not on dialysis. Renagel and Renvela are marketed in approximately 85 countries. In Japan and various Pacific Rim countries, Renagel is marketed by Chugai Pharmaceutical Co., Ltd and its sublicensee, Kyowa Hakko Kirin Co., Ltd. The main countries contributing to sales of Renagel and Renvela in 2015 were the U.S., France, Germany, Italy, Brazil and the U.K. Allegra/Telfast Allegra (fexofenadine hydrochloride) is a long-lasting (12- and 24-hour) non-sedating prescription anti-histamine for the treatment of seasonal allergic rhinitis (hay fever) and uncomplicated hives. It offers patients significant relief from allergy symptoms without causing drowsiness. The company also markets Allegra-D 12 Hour and Allegra-D 24 Hour, anti-histamine/decongestant combination products with an extended-release decongestant for non-drowsy relief of seasonal allergy symptoms, including nasal congestion. This combination is marketed in Japan under the Dellegra brand name. Generics of most forms of Allegra/Telfast have been approved in the company's major markets. In the U.S., the Allegra family moved to over-the-counter (OTC) use in adults and children two years of age and older in 2011. Allegra was also launched on the OTC market in Japan in 2012, though it also remains available on prescription. Allegra/Telfast is marketed in approximately 80 countries. The largest market for prescriptions of Allegra is Japan, where competing generics entered the market in early 2013. Stilnox/Ambien/Myslee Stilnox (zolpidem tartrate) is indicated in the short-term treatment of insomnia. Stilnox induces sleep that is qualitatively close to natural sleep and devoid of certain side effects that are characteristic of the benzodiazepine class as a whole. Its action lasts for a minimum of six hours, and it is generally well tolerated, allowing the patient to awaken without notably impaired attention, alertness or memory throughout the day. Stilnox is marketed in approximately 100 countries. It is available under the brand name Ambien/AmbienCR in the U.S. and Myslee in Japan, where it is co-promoted jointly with Astellas. Stilnox and Ambien CR are subject to generic competition in most markets, including the U.S. and Europe. In Japan, generics of Myslee entered the market in 2012. In 2015, the main countries contributing to Stilnox/Ambien/Myslee sales were Japan and the U.S. Synvisc/Synvisc-One Synvisc and Synvisc-One (hylan G-F 20) are viscosupplements used to treat pain associated with osteoarthritis. Synvisc is indicated for the treatment of pain associated with osteoarthritis (OA) of the knee, hip, ankle, and shoulder joint in countries that have adopted CE marking, and for pain due to knee osteoarthritis in the U.S. Synvisc-One is approved for use in patients with OA of the knee in U.S. and countries that require CE marking. The main viscosupplementation market is for the treatment of pain associated with osteoarthritis of the knee. Synvisc is a triple-injection product and Synvisc-One a single-injection product. Both are administered directly into the intra-articular space of the joint to temporarily restore synovial f
sanofi-adr (SNY:New York)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 42 96www.sanofi.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for SNY.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.